

UTSPH
COLLOQUIUM

Reporting Interim Safety Data

In spite of the many levels of monitoring for safety during the course of drug development, many important harms are not identified until after a drug goes on the market. In some sense, the problem is inevitable because rare events have a low probability of emerging in the relatively small sample sizes of even large trials. But can we do better during drug development? Statisticians have introduced a variety of sophisticated methods for the interim analysis of data on efficacy. In this talk ways will be discussed in which clinicians and statisticians can improve the reporting of data on safety during a trial.



Janet Wittes, PhD

Founder and President
Statistics Collaborative, Inc.
Washington, DC

Co-Author of the Monograph
Statistical Monitoring of Clinical Trials - a Unified Approach
by Proschan, Lan, and Wittes

Wednesday

November 4, 2009

12:00 – 1:00 p.m.

RAS Auditorium

The University of Texas School of Public Health
1200 Herman Pressler St., Houston, TX 77030

*Complimentary lunch provided for the first 50 attendees
Parking available at Texas Medical Center Garage 2*

Sponsors: UTSPH Academic Programs and Division of Biostatistics



THE UNIVERSITY of TEXAS
SCHOOL OF PUBLIC HEALTH